# Are Pharmacies the New Dispensary Model? Utah Thinks So > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/are-pharmacies-the-new-dispensary-model-utah-thinks-so/ > **Published:** 2026-09-07T07:18:00-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:45:26-04:00 > **Clinical Summary:** Utah explores pharmacies as a new dispensary model to ensure product consistency in medical cannabis use. Learn how this could impact patient care. --- ✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. CancerNeurologyPolicyResearchMental HealthSafetyPain Why This Matters This article matters to clinicians and their patients as it discusses a potential shift in cannabis distribution models, with pharmacies potentially becoming dispensaries. For patients with conditions like cancer or autoimmune diseases who rely on consistent cannabis products for treatment, this change could improve accessibility, safety, and quality of care. The evolution of the industry may also influence clinical practice guidelines and treatment options for these patients. Clinical Summary In Utah, a proposal suggests pharmacies as potential dispensaries for medical cannabis. This shift aims to ensure product consistency, particularly beneficial for patients with cancer, autoimmune diseases, and other serious conditions who rely on cannabis therapy for symptom management. The practical takeaway is that this change could potentially improve accessibility and quality of medical cannabis products for these vulnerable patient populations. Dr. Caplan’s Take “As a family physician specializing in cannabis medicine, I welcome the potential shift towards pharmacies as dispensaries. However, it’s crucial to ensure consistent product quality, particularly for patients managing complex conditions like cancer or autoimmune diseases, where treatment efficacy can significantly impact their wellbeing.” Clinical Perspective 💊🔬 In light of the article “Are Pharmacies the New Dispensary Model? Utah Thinks So”, it’s worth noting that the potential shift towards pharmacies for cannabis distribution could have significant implications for healthcare providers. This change may offer improved accessibility and standardization, particularly beneficial for patients with cancer, autoimmune diseases, and other serious conditions who rely on consistent cannabis products for symptom management. However, it’s crucial to acknowledge the complexity of this transition, including potential regulatory hurdles, product quality concerns, and the need for comprehensive education for pharmacists to ensure safe and effective use. In clinical practice, healthcare providers should remain vigilant in monitoring patient responses to cannabis treatments, adjusting dosages as necessary, and collaborating with pharmacists to optimize care in this evolving landscape. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/medical-illness/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Are%20Pharmacies%20the%20New%20Dispensary%20Model%3F%20Utah%20Thinks%20So%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D90844)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D90844)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Are%20Pharmacies%20the%20New%20Dispensary%20Model%3F%20Utah%20Thinks%20So%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D90844)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) 📰 Source: [https://cannabisindustryjournal.com/feature_article/are-pharmacies-the-new-dispensary-model-utah-thinks-so/](https://cannabisindustryjournal.com/feature_article/are-pharmacies-the-new-dispensary-model-utah-thinks-so/) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).